September 8, 2025 — Leads & Copy — CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) has administered a second dose in the second patient in the first cohort of its Phase 1 CER-1236 clinical trial for acute myeloid leukemia (AML).
The multi-dose intensification, authorized by the study’s Institutional Review Board (IRB), follows review of initial pharmacokinetic data from the first two enrolled patients showing cell expansion. It will effectively double the amount of cell product infused in each subject.
CERo’s Chief Medical Officer, Robert Sikorski, M.D., Ph.D., stated the modification will allow evaluation of the feasibility and safety of multiple infusions of CER-1236 in AML patients and to assess the implications of increased dosing. Study investigator Abhishek Maiti, M.D., presented a poster outlining the study protocol at the Society of Hematologic Oncology’s 13th annual meeting in Houston, Tex.
CERo CEO Chris Ehrlich noted the enhancement to the Phase 1 protocol represents meaningful progress. The company is preparing to enroll the third patient in the cohort and believes CER-1236 represents a potentially novel approach to cancer treatment.
The Phase 1/1b study is designed to evaluate the safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory AML, or in remission with measurable residual disease, or newly diagnosed patients with TP53 mutated MDS/AML or AML.
Chris Ehrlich, Chief Executive Officer, chris@cero.bio; Investors: CORE IR, investors@cero.bio
Source: CERo Therapeutics Holdings, Inc.
